Monitoring lung function in childhood cancer patients
Prospective Multicentre Cohort Study of Early Pulmonary Dysfunction in Childhood Cancer Patients (SWISS-Pearl Study)
This study is trying to see how different cancer treatments affect lung health in children with cancer by regularly checking their lung function and symptoms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 140 (estimated) |
| Ages | 4 Years to 22 Years |
| Sex | All |
| Sponsor | University Children's Hospital Basel Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 5 sites (Basel and 4 other locations) |
| Trial ID | NCT05427136 on ClinicalTrials.gov |
What this trial studies
This observational study aims to prospectively monitor lung function in childhood cancer patients following their diagnosis. It will assess the impact of various cancer treatments on pulmonary dysfunction using non-invasive methods such as lung function tests, lung imaging, and breath analysis, along with clinical symptom questionnaires. The study will collect data at multiple time points to evaluate changes in lung health over time.
Who should consider this trial
Good fit: Ideal candidates include childhood cancer patients who have undergone treatments such as chest radiation, chemotherapy, HSCT, or thoracic surgery.
Not a fit: Patients who have not received any of the specified cancer treatments or those with respiratory insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of pulmonary dysfunction in childhood cancer survivors.
How similar studies have performed: While this approach is observational and focuses on a specific patient population, similar studies have shown success in monitoring long-term health outcomes in cancer survivors.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * at least one of the following cancer treatments: * chest radiation * treatment with any kind of chemotherapy * hematopoietic stem cell transplantation (HSCT) * thoracic surgery * consent for Childhood Cancer Registry (ChCR) registration Exclusion Criteria: * no signed informed consent * Operation outside the chest area as only cancer treatment * Relapsed cancer (patients who develop relapse during the study will not be excluded) * In addition for MRI and lung function tests: * Subjects who are respiratory insufficient and cannot perform a lung function test (less than 92% O2 saturation; under O2 therapy) * Pregnant * MRI measurement not possible without sedation * Metal (e.g. pacemaker) in the body
Where this trial is running
Basel and 4 other locations
- University Children's Hospital Basel (UKBB) — Basel, Switzerland (Recruiting)
- Universitätsklinik für Kinderheilkunde — Bern, Switzerland (Recruiting)
- Geneva University Hospital — Geneva, Switzerland (Recruiting)
- Centre hospitalier universitaire vaudois Lausanne — Lausanne, Switzerland (Recruiting)
- Universitäts-Kinderspital Zürich — Zurich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Jakob Usemann, PD Dr. med. — University Children's Hospital Basel
- Study coordinator: Jakob Usemann, PD Dr. med.
- Email: jakob.usemann@ukbb.ch
- Phone: +41 61 704 12 12
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.